TMCnet News
2018 Multiple Myeloma Pipeline Highlights - ResearchAndMarkets.comThe "Multiple Myeloma Pipeline Highlights - 2018" report has been added to ResearchAndMarkets.com's offering. 'Multiple Myeloma Pipeline Highlights - 2018' provides the most up-to-date information on key pipeline products in the global Multiple Myeloma market. It covers emerging therapies for Multiple Myeloma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing dals. Clinical Trial Stages The report provides Multiple Myeloma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage. Drug Mechanism Classes The report provides Multiple Myeloma pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds. Company The report provides Multiple Myeloma pipeline products by the company. Short-term Launch Highlights Find out which Multiple Myeloma pipeline products will be launched in the US and Ex-US till 2020. For more information about this report visit https://www.researchandmarkets.com/research/tzfc75/2018_multiple?w=4 View source version on businesswire.com: https://www.businesswire.com/news/home/20180419005892/en/ |
